Lacrimal Apparatus Diseases (Epiphora)

07/01/2011 - "Operations were considered as successful when the irrigating fluid could pass through the lacrimal passage and the disappearance of dye was observed in dye disappearance test and the patients' epiphora symptoms improved 3 months postoperatively. "
01/01/2013 - "Primary outcome measures included were anatomical patency on irrigation and relief from epiphora assessed subjectively and also objectively by a dye disappearance test. "
01/01/2023 - "Relief of epiphora and positive dye test were established as functional and anatomical successes, respectively. "
01/01/2023 - "Parameters for success were analyzed based on patency on irrigation, functional endoscopic dye test, and improvement of epiphora. "
09/01/2021 - "Surgical success was defined as the patients' subjective report of relief of epiphora and objective endoscopic confirmation of ostium patency confirmed by a positive functional dye test. "

01/01/2003 - "In concert with these changes, moisturizing agent usage and corneal/conjunctival fluorescein staining decreased in a progressive fashion over the 8-week study period, and best-corrected visual acuity, ocular comfort, and visual performance improved in the absence of any treatment-related adverse events except for one case of epiphora. "
01/01/2021 - "Postoperative anatomical success assessing the punctum size, functional success using the fluorescein disappearance test (FDT), and patient satisfaction based on epiphora scoring were recorded. "
01/01/2021 - "Functional success was defined by an absence of additional AD episodes, no epiphora, and ostium patency as established via endoscopic evaluation or fluorescein irrigation. "
08/01/2013 - "All patients were free of epiphora and patent to syringing, with nasal endoscopy revealing free flow of fluorescein through the ostium at a mean follow-up of 11.3 months (median follow-up 9 months). "
01/01/2011 - "17/18 (94.4%) cases were free of epiphora at median follow-up of 12 months (range 2-36), with nasal endoscopy revealing free flow of fluorescein through the ostium in 17/18 (94.4%) of cases. "

08/01/2019 - "Otherwise, the silicone tube was removed three months after surgery, and after further follow up of 8 weeks, 94 per cent of the study population reported complete remission of epiphora. "
07/01/2011 - "Relief of epiphora by silicone tube intubation using a Nunchaku-style tube treatment significantly improved the vision-related quality of life in patients with lacrimal passage obstructions."
06/01/2007 - "Lacrimal silicone intubation is a simple safe and effective procedure for patients with epiphora even after anatomically successful DCR."
11/01/2012 - "The majority of patients with canalicular problems are relieved of epiphora after silicone tube removal. "
01/01/2019 - "All patients presented with epiphora (100%) and underwent external DCR and were chosen for conventional surgery (n = 33, 51%, group 1) or Pawar silicone implant surgery (n = 32, 49%, group 2) on a random basis. "

10/01/2022 - "To compare the efficacy of botulinum toxin A (BoNTA) injection into the lacrimal gland versus lateral tarsal strip (LTS) for functional epiphora. "
08/01/2016 - "PurposeTo investigate and compare the efficacy of botulinum toxin-A injection in the lacrimal gland and conjunctivodacryocystorhinostomy surgery for the treatment of epiphora caused by proximal lacrimal system obstruction.MethodsCharts of the patients with proximal canalicular obstruction who had undergone conjunctivodacryocystorhinostomy with permanent tube insertion (18 patients, group 1) or 4 units of botulinum toxin-A injection in the palpebral lobe of the lacrimal gland (20 patients, group 2) were reviewed retrospectively. "
10/01/2022 - "Treatment for functional epiphora with botulinum toxin-A versus lateral tarsal strip in a randomized trial."
01/01/2021 - "The purpose of this study was to determine and compare the effects between injecting botulinum toxin A (BTX-A) transconjunctivally into the palpebral lobe and transcutaneously into the orbital lobe of the lacrimal gland in patients with epiphora due to lacrimal outflow obstruction. "
09/01/2003 - "The purpose of this study was to investigate the hitherto undescribed effects of botulinum toxin A injected into the lacrimal gland in patients with functional epiphora. "

03/01/2011 - "Botulinum toxin injection in the palpebral lobe of the lacrimal gland can be used effectively and safely for symptomatic epiphora due to lacrimal obstruction and gustatory tearing. "
04/01/2022 - "This review seeks to examine the safety and efficacy of botulinum toxin injection for management of chronic epiphora. "
09/01/2023 - "One of them is the use of Inj Botulinum toxin, but there are very few studies that have explored its role in treating post-traumatic epiphora. "
01/01/2023 - "Epiphora in the fourth patient resolved with botulinum toxin injection in the lacrimal gland. "
01/01/2023 - "Letter to the editor regarding the article: "Lacrimal gland botulinum toxin injection for epiphora management"."

06/01/2007 - "To evaluate the safety and efficacy of mitomycin-C irrigation after balloon dacryocystoplasty in the treatment of epiphora caused by obstruction of the lacrimal system. "
01/01/2002 - "Efficacy of probing the nasolacrimal duct with adjunctive Mitomycin-C for epiphora in adults."
11/01/2004 - "Epiphora as a side effect of topical mitomycin C."
01/01/2002 - "Our experience suggests good long-term results for probing with adjunctive, topical Mitomycin-C for cases of adult epiphora caused by obstruction of the nasolacrimal duct followed by repeat procedure if necessary. "
02/01/1993 - "The epiphora resolved and the puncta remained patent after the patient underwent a third one-snip procedure, supplemented with topical mitomycin during and after surgery."

07/01/2006 - "The purpose of this study was to evaluate, in a prospective, single-center study, the effectiveness of Song's polyurethane stents, modified "in-house," in the percutaneous management of epiphora. "
06/01/2006 - "Eighty-five patients underwent fluoroscopally-guided placement of polyurethane stent in 86 lacrimal systems for the treatment of severe idiopathic obstructive epiphora. "
03/15/2006 - "Polyurethane stent obstruction as a cause of recurrent epiphora. "
09/01/2005 - "Balloon dacryocystoplasty and nasolacrimal polyurethane stent placement are the main fluoroscopically guided interventions for the treatment of epiphora by recanalizing the obstructed LDS. "
11/01/2003 - "Based on our preliminary experience, temporary placement of polyurethane stents would not appear to be an efficacious therapeutic option for treating epiphora caused by post-saccal obstruction."

04/01/2018 - "Patients with intractable epiphora despite patent lacrimal ducts can be effectively treated with BoNT/A (IncobotulinumtoxinA) injection into the palpebral lobe of the lacrimal gland. "
04/01/2018 - "More studies are needed to delineate which types of epiphora can be treated with BoNT A."
10/01/2017 - "More studies are needed to delineate which types of epiphora can be treated with BoNT/A."
04/01/2018 - "Sixty-five palpebral lacrimal glands of forty-two patients with epiphora despite patent lacrimal ducts, of mean age 65 years, sex ratio 0.8, were treated with BoNT/A (IncobotulinumtoxinA, XEOMIN®, MERZ Pharma France) from April 2009 to April 2016. "
10/01/2017 - "Patients with epiphora can be treated effectively with BoNT/A to reduce lacrimal secretion of the principal lacrimal gland in its palpebral portion. "

01/01/2022 - "Success was defined as the absence of epiphora and the normalization of an earlier delayed FDDT after surgery. "
01/01/2019 - "At a mean age of 4.9 years, all children had epiphora and discharge with MoE (both upper and lower), raised TFH and positive FDDT. "
01/01/2014 - "There was no significant difference between the epiphora scorings and FDDT results in postoperative visits among the groups. "
05/01/2013 - "There was no statistically significant correlation between severity of epiphora and age with FDDT. "
05/01/2013 - "FDDT and severity of epiphora were graded. "

10/15/2013 - "Argema mimosae, Anaphe panda and Epiphora bauhiniae showed lower solubility across the solution systems used. "
07/01/1997 - "Local conjunctival application of gadolinium solution allows functional tests of the lacrimal duct system in patients suffering from epiphora."
11/01/2010 - "0.2 mg/ml Mitomycin-C solution of was the most effective medication for office probing and syringing in reducing epiphora symptom in nasolacrimal duct obstruction patients."
12/01/2018 - "Surgical success was defined when the following postoperative conditions were satisfied: no epiphora, normal tear meniscus height, and complete clearance of the dye 5 min after instilling a drop of 2% fluorescein solution into the inferior conjunctional fornix. "
03/01/2015 - "We report a 23-month old girl who presented with bilateral epiphora who underwent bilateral lacrimal probing and syringing, during which a cocaine adrenaline solution was used. "

02/01/2017 - "Endoscopic dacryocystorhinostomy offers good success rates with a safety profile and efficacy equivalent to the traditional external approach is an effective treatment with good outcome results in adults and children with persistent or functional epiphora."
05/01/2007 - "In this prospective series, transcanalicular dacryocystorhinostomy was effective in treatment of epiphora in adults with little morbidity."
03/01/1979 - "Dacryocystorhinostomy is used in the effective treatment of epiphora secondary to obstruction of the lacrimal drainage system. "
07/01/2023 - "Endonasal dacryocystorhinostomy is an effective and safe technique for the treatment of epiphora, and this study has provided a suggested protocol for management of patients presenting with epiphora."
02/01/2017 - "To assess unenhanced magnetic resonance imaging (MRI) in the preoperative evaluation of obstructive epiphora in patients undergoing dacryocystorhinostomy (DCR) and in particular, to evaluate the efficacy of this technique in the detection of the exact level of obstruction occurring in the naso-lachrymal duct (NLD). "

11/01/2003 - "Stent failure does not preclude subsequent treatment options and is an excellent first-line treatment of epiphora."
11/01/1998 - "The epiphora was completely resolved in 13 cases and partially relieved in four; there were three cases of stent obstruction. "
01/01/2002 - "The low patency rate and the difficulties encountered in removing nasolacrimal stents during the course of long-term placement calls into question the efficacy of this method as a definitive treatment for epiphora caused by obstruction of the lacrimal drainage system, although studies comparing this and other treatment modalities are needed. "
01/01/2012 - "We evaluated the efficacy of topical contrast-enhanced MR DCG in comparison with DS DCG in patients with obstructive epiphora who underwent balloon DCG or stent placement. "
09/01/1998 - "After stent removal, 73 (51%) of the 142 lacrimal systems showed improvement of epiphora, with a patent lacrimal system at 7-day follow-up dacryocystography. "

11/01/2005 - "Seven of 11 patients showed an improvement in epiphora scores with topical therapy. "
07/01/2023 - "Lacrimal Gland Therapies for Refractory Epiphora: Current Understanding."
05/01/2023 - "Lacrimal gland targeted therapies for refractory epiphora: quantitative changes in the gland activity."
02/01/2011 - "[Investigation of epiphora following S-1 therapy]."
11/01/2010 - "Herein we present the subjective and objective findings of 243 consecutive patients with non-irritative induced epiphora, who underwent an operation in a standardised therapy scheme, which is used at the eye departments of the Universities of Lübeck and Würzburg. "

11/01/2010 - "The main outcome measure was resolution or improvement of the epiphora and no major laser damage intranasally. "
03/01/2007 - "The main outcome measure was resolution or improvement of epiphora and no major laser damage intranasally. "
07/01/2006 - "We do not advocate the use of laser in endonasal DCR for patients with epiphora. "
10/01/2005 - "Three months postoperatively (n=38), total relief of epiphora among the nonlaser group was 80.76 vs 75% in the laser group (P=0.982). "
03/01/2009 - "The aim of this postal questionnaire study was to compare the health status of patients treated for epiphora by external versus endonasal non-laser dacryocystorhinostomy. "

08/01/2001 - "In our experience, transplantation of preserved human amniotic membrane greatly improved symptoms of epiphora caused by conjunctivochalasis. "
04/01/2019 - "BTXA injection can decrease the secretion of transplanted SMG significantly, relieving the symptoms of epiphora; 25U BTXA is a suitable dose to treat 'opportunistic epiphora' after SMG transplantation."
04/01/2019 - "Fifteen patients with epiphora after SMG transplantation were separated to three groups, and received 15U, 20U and 25U BTXA injection in the transplanted SMG, respectively. "
02/18/2018 - "In order to resolve two main clinical problems including ductal obstruction resulted from low secretion rate during the latent period, and epiphora due to over secretion of the transplanted SMG in the later term of transplantation, the regulation of the secretion mechanism of the normal and transplanted SMG were investigated. "
02/18/2018 - "A novel surgical modality of partial transplantation of SMG was established to prevent postoperative epiphora. "